Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Mitsubishi, J&J to End Stelara Co-Promotion in Japan at Year-End
September 17, 2025
- ASKA Presses Dalton Again for Stake Plan Details after Public Statement
September 17, 2025
- Daiichi Bags FDA Breakthrough Therapy Status for Anti-CDH6 ADC
September 17, 2025
- AbbVie Japan Seeks Rinvoq Label Expansion for Polyarticular JIA
September 16, 2025
- Clenafin Authorized Generic Hits Japan Market: Kaken
September 16, 2025
- Lilly Confirms Safety of Oral GLP-1 Orforglipron in Japan PIII
September 16, 2025
- Pfizer’s Ulcerative Colitis Drug Velsipity Now Available in Japan
September 16, 2025
- Predictability Key to Novartis’ Japan Investment, Says International Chief
September 16, 2025
- Eisai Sees “Best-in-Class” Promise for E2086 as Once-Daily Narcolepsy Drug
September 12, 2025
- LEO Pharma Reinforces Japan Push toward Dermatology Leadership
September 12, 2025
- Enhertu’s Tumor-Agnostic Use Now under EU Review: Daiichi Sankyo
September 12, 2025
- Sawai, Nichi-Iko to Consolidate 15 APIs as Sector Tackles Small-Lot Production
September 11, 2025
- Sawai and T’s Pharma Won Forxiga Generics by Skirting Patent, Will the Strategy Hold?
September 11, 2025
- Welireg Expected to Preserve Organ Function in VHL Disease: Urologist
September 11, 2025
- Sobi Japan Targets Five Rare Diseases in Five Years, Says President
September 10, 2025
- Teijin Pharma Bets on Ascendis Rare Disease Assets as Feburic Sales Crumble
September 10, 2025
- Gilead Says It Has No Intention to Scrap License Deal: Carna Bio
September 10, 2025
- Teikoku to Take Over Janssen’s Lopemin in Japan
September 10, 2025
- Nippon Shinyaku’s EGPA Drug Bags Fast-Track Status in US
September 10, 2025
- Lilly Japan Ramps Up Seishin Plant with New Building and Packaging Line
September 9, 2025
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…